Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 3/20 | 0.35 |
| ▸ | HTR2B | P41595 | 3/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23554749 | 0.79 | CHRM2 (0.40) | HTR2ACHRM2CHRM3HTR2CHTR2B | |
| SCHEMBL171143 | 0.79 | CHRM2 (0.40) | HTR2ACHRM2CHRM3HTR2CHTR2B | |
| SCHEMBL171650 | 0.73 | NISCH (0.37) | HTR2ACHRM2CHRM3HTR2CHTR2B | |
| SCHEMBL171358 | 0.71 | HTR2A (0.41) | HTR2ACHRM2CHRM3HTR2CHTR2B | |
| SCHEMBL169474 | 0.71 | HTR2A (0.41) | HTR2ACHRM2CHRM3HTR2CHTR2B | |
| SCHEMBL13591415 | 0.71 | CHRM3 (0.49) | HTR2ACHRM2CHRM3 | |
| SCHEMBL13490467 | 0.68 | HTR2A (0.38) | HTR2ACHRM2CHRM3HTR2CHTR2B | |
| SCHEMBL13490471 | 0.67 | PIM1 (0.47) | CHRM2CHRM3 | |
| SCHEMBL29814719 | 0.66 | HTR2A (0.37) | HTR2ACHRM2CHRM3HTR2CHTR2B | |
| SCHEMBL23089359 | 0.66 | HTR2A (0.37) | HTR2ACHRM2CHRM3HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426120-A1 | Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them | Fujifilm Finechemicals Co., Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100029947-A1 | Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them | FUJIFILM FINECHEMICALS CO., LTD | 2010-02-04 | — | — | US | disclosed |
| US-7632950-B2 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2009-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029947-A1 | Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them | QDPR, HRH4, HRH2 | HTR2A 177/4885CHRM2 629/4885CHRM3 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.